| Identification | Back Directory | [Name]
CPUY074020 | [CAS]
902279-44-1 | [Synonyms]
CPUY074020
3-(1-Piperidyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]-6H-anthra[1,9-cd]isoxazol-6-one
6H-Anthra[1,9-cd]isoxazol-6-one, 3-(1-piperidinyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- | [Molecular Formula]
C25H28N4O2 | [MDL Number]
MFCD14777686 | [MOL File]
902279-44-1.mol | [Molecular Weight]
416.52 |
| Chemical Properties | Back Directory | [Boiling point ]
677.6±55.0 °C(Predicted) | [density ]
1.305±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.90±0.20(Predicted) | [color ]
Brown to dark brown |
| Hazard Information | Back Directory | [Uses]
CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase G9a, with an IC50 of 2.18 μM. CPUY074020 possesses anti-proliferative activity[1]. | [in vivo]
CPUY074020 exhibits reasonable PK properties, with an oral bioavailability of 55.5% and a T1/2 value of 4.0 hours at an oral dose of 10 mg/kg[1].
| Animal Model: | Mice | | Dosage: | 10 mg/kg | | Administration: | Oral administration | | Result: | t1/2=4.0 hours |
| [IC 50]
EHMT2/G9a/KMT1C | [References]
[1] Chen WL, et al. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular. Bioorg Med Chem. 2016 Nov 15;24(22):6102-6108. DOI:10.1016/j.bmc.2016.09.071 |
|
|